AGX Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 198850 1 Year 0.03 300.00
52 Week High 0.06
52 Week Low 0.01
AGX Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
GPP 0.03 0.00%
PDN 0.06 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
GMR 0.01 0.00%
GMR 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
RMG 0.02 100.00%
RMG 0.02 100.00%
GME 0.03 50.00%
GME 0.03 50.00%
GME 0.03 50.00%
GME 0.03 50.00%
RHT 0.03 50.00%
RHT 0.03 50.00%
BMN 0.03 50.00%
More..
ASX Australia Top Losers Stocks
HOG 0.00 -100.00%
HOG 0.00 -100.00%
PCL 0.00 -100.00%
PCL 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GTG 0.01 -50.00%
More..

Agenix Ltd (ASX: AGX)

AGX Technical Analysis 3
As on 17th Nov 2016 AGX Share Price closed @ 0.04 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.02 & Buy for SHORT-TERM with Stoploss of 0.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
AGX Target for December
1st Target up-side 0.04
2nd Target up-side 0.04
3rd Target up-side 0.04
1st Target down-side 0.04
2nd Target down-side 0.04
3rd Target down-side 0.04
AGX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.agenix.com
AGX Address
AGX
156 Collins Street
Ground Floor
Melbourne, VIC 3000
Australia
Phone: 61 3 8616 0379
Fax: 61 3 8616 0382
AGX Latest News
Interactive Technical Analysis Chart Agenix Ltd ( AGX ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Agenix Ltd
AGX Business Profile
Agenix Limited, a biotechnology company, provides next generation drugs and diagnostics primarily in Australia and the People’s Republic of China. The company operates through AGX-1009, ThromboView, and DiagnostIQ segments. The AGX-1009 segment is involved in developing an anti-viral drug for the treatment of hepatitis B patients, which is a patented novel targeted prodrug analog of an existing compound, Tenofovir and has completed pre-clinical trials. The ThromboView segment develops a monoclonal antibody related to the detection of blood clots. The DiagnostIQ segment offers DiagnostIQ, a rapid point-of-care diagnostic technology for a various human health applications. Agenix Limited is based in Melbourne, Australia.